Skip to main content
. 2023 Jul 7;10:1206279. doi: 10.3389/fcvm.2023.1206279

Figure 4.

Figure 4

GMP-EV treatment moderates left ventricular dilatation upon rats doxorubicin exposure. (A) LVESV and (B) LVEDV measured by echocardiography and expressed as a percent change (Median+/−IQR) from day 10 (post-DOX administration). Sham: n = 6; DOX+Placebo: n = 11, DOX+GMP-EV: n = 12. *p ≤ 0.05; (Kruskal Wallis with Dunn's correction test). LV-ESV/LV-EDV, left ventricular-systolic/diastolic function.